Antisynthetase (AS) syndrome is a clinically heterogeneous form of idiopathic inflammatory myopathy characterized by myositis, arthralgia, Raynaud phenomenon, mechanic hands, interstitial lung disease...
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation on antisynthetase syndrome is limited due to its rarity, affecting fewer than 10 individuals per 100,000. This rarity restricts the scope of systematic clinical studies and comprehensive research. Furthermore, the genetic basis of the condition remains unidentified, complicating the characterization of its clinical features. As research continues, there is hope for better understanding and management of this condition.
The clinical features of antisynthetase syndrome are diverse and primarily affect the muscular and respiratory systems. Common symptoms include myalgia, muscle weakness, and myositis, all observed in 80-99% of patients. Additionally, respiratory issues such as cough and respiratory insufficiency are prevalent, alongside interstitial lung disease and pulmonary fibrosis. Patients may also experience arthralgia and chest pain, further complicating the clinical picture.
To navigate your care effectively, consider seeking a specialist in autoimmune diseases or a rheumatologist with experience in inflammatory myopathies. Engaging with clinical trials could also be beneficial, as they may offer access to new therapies. For additional resources, visit the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov, which provides valuable information on rare conditions. Although there are no identified patient organizations for antisynthetase syndrome, connecting with broader autoimmune disease communities may provide support and shared experiences.
Currently, there are 6 active clinical trials investigating various aspects of antisynthetase syndrome. These trials aim to explore new treatment options and improve patient outcomes. You can find more information about these trials by visiting ClinicalTrials.gov and searching for antisynthetase syndrome. While there are no orphan drugs designated for this condition, participation in clinical trials may provide access to cutting-edge therapies.
Actionable guidance for navigating care for antisynthetase syndrome
To navigate your care effectively, consider seeking a specialist in autoimmune diseases or a rheumatologist with experience in inflammatory myopathies. Engaging with clinical trials could also be beneficial, as they may offer access to new therapies. For additional resources, visit the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov, which provides valuable information on rare conditions. Although there are no identified patient organizations for antisynthetase syndrome, connecting with broader autoimmune disease communities may provide support and shared experiences.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on antisynthetase syndrome is limited due to its rarity, affecting fewer than 10 individuals per 100,000. This rarity restricts the scope of systematic clinical studies and comprehensive research. Furthermore, the genetic basis of the condition remains unidentified, complicating the characterization of its clinical features. As research continues, there is hope for better understanding and management of this condition.
The clinical features of antisynthetase syndrome are diverse and primarily affect the muscular and respiratory systems. Common symptoms include myalgia, muscle weakness, and myositis, all observed in 80-99% of patients. Additionally, respiratory issues such as cough and respiratory insufficiency are prevalent, alongside interstitial lung disease and pulmonary fibrosis. Patients may also experience arthralgia and chest pain, further complicating the clinical picture.
To navigate your care effectively, consider seeking a specialist in autoimmune diseases or a rheumatologist with experience in inflammatory myopathies. Engaging with clinical trials could also be beneficial, as they may offer access to new therapies. For additional resources, visit the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov, which provides valuable information on rare conditions. Although there are no identified patient organizations for antisynthetase syndrome, connecting with broader autoimmune disease communities may provide support and shared experiences.
Currently, there are 6 active clinical trials investigating various aspects of antisynthetase syndrome. These trials aim to explore new treatment options and improve patient outcomes. You can find more information about these trials by visiting ClinicalTrials.gov and searching for antisynthetase syndrome. While there are no orphan drugs designated for this condition, participation in clinical trials may provide access to cutting-edge therapies.
Actionable guidance for navigating care for antisynthetase syndrome
To navigate your care effectively, consider seeking a specialist in autoimmune diseases or a rheumatologist with experience in inflammatory myopathies. Engaging with clinical trials could also be beneficial, as they may offer access to new therapies. For additional resources, visit the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov, which provides valuable information on rare conditions. Although there are no identified patient organizations for antisynthetase syndrome, connecting with broader autoimmune disease communities may provide support and shared experiences.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on antisynthetase syndrome is limited due to its rarity, affecting fewer than 10 individuals per 100,000. This rarity restricts the scope of systematic clinical studies and comprehensive research. Furthermore, the genetic basis of the condition remains unidentified, complicating the characterization of its clinical features. As research continues, there is hope for better understanding and management of this condition.
The clinical features of antisynthetase syndrome are diverse and primarily affect the muscular and respiratory systems. Common symptoms include myalgia, muscle weakness, and myositis, all observed in 80-99% of patients. Additionally, respiratory issues such as cough and respiratory insufficiency are prevalent, alongside interstitial lung disease and pulmonary fibrosis. Patients may also experience arthralgia and chest pain, further complicating the clinical picture.
To navigate your care effectively, consider seeking a specialist in autoimmune diseases or a rheumatologist with experience in inflammatory myopathies. Engaging with clinical trials could also be beneficial, as they may offer access to new therapies. For additional resources, visit the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov, which provides valuable information on rare conditions. Although there are no identified patient organizations for antisynthetase syndrome, connecting with broader autoimmune disease communities may provide support and shared experiences.
Currently, there are 6 active clinical trials investigating various aspects of antisynthetase syndrome. These trials aim to explore new treatment options and improve patient outcomes. You can find more information about these trials by visiting ClinicalTrials.gov and searching for antisynthetase syndrome. While there are no orphan drugs designated for this condition, participation in clinical trials may provide access to cutting-edge therapies.
Actionable guidance for navigating care for antisynthetase syndrome
To navigate your care effectively, consider seeking a specialist in autoimmune diseases or a rheumatologist with experience in inflammatory myopathies. Engaging with clinical trials could also be beneficial, as they may offer access to new therapies. For additional resources, visit the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov, which provides valuable information on rare conditions. Although there are no identified patient organizations for antisynthetase syndrome, connecting with broader autoimmune disease communities may provide support and shared experiences.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
Organizations with orphan designations or approved therapies for this disease